Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation, Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose, Intravenously Administered MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2014
Price :
$35
*
At a glance
- Drugs Sifalimumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors MedImmune
- 19 Dec 2014 New trial record